Business Trends– category –
-
Company Announces Positive Safety and Early Efficacy Signals in Phase 1 Clinical Trial of iPSC-Derived Retinal Cell Therapy, Aims for Phase 2 This Year
Endpoints News USA Overview A cell therapy development company has reported favorable safety data and initial efficacy signals from its ongoing Phase 1 clinical trial of an iPSC-derived cell therapy for a specific ocular disease. This th... -
Major Pharmaceutical Company Forges Strategic Alliance with Gene-Editing Biotech to Accelerate Multi-Disease In Vivo Gene Editing Therapy Development
Fierce Biotech USA Overview A leading pharmaceutical company announced a strategic partnership with a biotech firm specializing in gene-editing technology. This alliance aims for the co-development of in vivo gene-editing therapies acros... -
Stealth Cell Therapy Startup Secures Series B, Accelerating iPSC-Derived Neurodegenerative Candidate Towards IND
Specialized Media / Company Announcement USA Overview An undisclosed cell therapy startup has successfully closed its Series B funding round, securing substantial capital. This investment will accelerate preclinical development and suppo... -
WuXi Advanced Therapies Significantly Expands Cell Therapy Manufacturing Capacity to Meet Surging Client Demand, Reinforcing GMP Capabilities and Process Development
WuXi Advanced Therapies China Overview WuXi Advanced Therapies announced a substantial expansion of its cell therapy manufacturing facilities. This significant investment aims to address the growing demand from clients for complex cell t... -
Thermo Fisher Scientific Dramatically Expands Global Cell and Gene Therapy CDMO Manufacturing Capacity with Enhanced Automation
Thermo Fisher Scientific USA Overview Thermo Fisher Scientific has significantly expanded its global manufacturing network for cell and gene therapy products to meet surging demand. This strategic move aims to provide advanced manufactur... -
Unlocking Exosome Therapies for Corneal Disorders: Overcoming the Clinical Translation Challenge
Annals of Translational Medicine China Overview A recent review in *Annals of Translational Medicine* underscores the significant hurdles facing exosome-based therapies for corneal disorders, primarily in achieving manufacturing standard... -
Gene Editing Startup Race Intensifies: CRISPR Therapeutics Leads in Commercialization, Intellia Advances In Vivo Phase 3, Beam Demonstrates Base Editing Versatility Across Human Therapies
New Market Pitch USA Overview A New Market Pitch analysis reveals CRISPR Therapeutics leads in commercialization with approved therapies, while Intellia Therapeutics shows significant progress in Phase 3 in vivo gene editing trials. Beam... -
BioInformant Details 2026 iPSC-Derived Cell Therapeutics Pipeline: Key Players Accelerate Clinical Development for Parkinson’s, Heart Failure, Cancer, and More
BioInformant USA Overview BioInformant's comprehensive report outlines the 2026 pipeline for iPSC-derived cell therapeutics, highlighting progress from key companies like Fate Therapeutics, BlueRock Therapeutics, FUJIFILM Cellular Dynami... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c... -
ARPA-H Launches AEGIS Project: Affordable Gene-Editing Therapies for Pediatric Immune Diseases via CRISPR and LNP Delivery
Princeton University USA Overview The ARPA-H THRIVE-funded AEGIS project is pioneering the development of affordable gene-editing therapies for children suffering from rare inborn errors of immunity (IEIs). By leveraging advanced CRISPR ...
